ASCO GI 2023 | REFINE: a real-world analysis of regorafenib in patients with unresectable HCC

Richard Finn, MD, University of California, Los Angeles, CA, presents the final analysis of the prospective, observational REFINE trial (NCT03289273), which evaluated regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice. Regorafenib was routinely administered in the second-line setting, often after patients progress on sorafenib, where survival was higher in the second-line setting. Reported safety and overall survival were additionally comparable to the data from the RESORCE trial (NCT01774344). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.